

Fiscal quarter ended June 2018
– supplementary financial summary –

August 2, 2018

Asahi Kasei Corporation

Focus for consolidated results for fiscal quarter ended June 2018

AsahiKASEI

Results for first quarter

New records in Q1 for net sales, operating income, ordinary income, and net income attributable to owners of the parent.

- ✓ Material segment: Sales and operating income increased
In Fibers, increased shipments of Lamous microfiber suede and Bemliese continuous-filament cellulose nonwoven. In Chemicals, improved terms of trade for, and increased shipments of, acrylonitrile. In Electronics, increased shipments of Li-ion battery separator.
- ✓ Homes segment: Sales and operating income flat
Decreased deliveries of unit homes. Firm performance of rental management and condominium construction in real estate.
- ✓ Health Care segment: Sales and operating income increased
In medical devices, increased shipments of Planova virus removal filters. In Critical Care, increased shipments of defibrillators for professional use, and firm performance of LifeVest wearable defibrillator business.

Forecast for first half

Expecting record highs in H1 for net sales, operating income, ordinary income, and net income, with all items exceeding the forecast in May 2018. Operating income revised upward in all three segments.

Highlights

Decision to acquire Sage Automotive Interiors, Inc., a US-based manufacturer of automotive interior material, for expansion of automotive-related business. (As the acquisition has not yet closed, there is no effect on Q1 earnings and H1 forecast.)

Contents

1. Consolidated results for fiscal quarter ended June 2018

6	Summary of financial results
7	Statements of income
8	Balance sheets
9	Cash flows
10	Sales and operating income by segment
11-12	Sales and operating income increase/decrease by business category
13-19	Overview of results by business category

2. Forecast for first half fiscal 2018

21	Consolidated operating performance forecast
22	Sales and operating income forecast by segment
23-24	Sales and operating income forecast by business category

3. Appendix

26-27	Quarterly sales and operating income by business category
28	Overseas sales by business category
29	Extraordinary income and loss
30-32	Reference materials for Homes and Health Care

– Disclaimer –

The forecasts and estimates shown in this document are dependent on a variety of assumptions and economic conditions. Plans and figures depicting the future do not imply a guarantee of actual outcomes.



1. Consolidated results for fiscal quarter ended June 2018

Summary of financial results

(¥ billion, unless otherwise specified)

	Q1 2017	Q1 2018	Q1 2018 vs. Q1 2017	
			Increase (decrease)	% change
Net sales	448.7	489.8	41.0	+9.1%
Operating income	37.9	47.9	10.0	+26.5%
Ordinary income	41.2	51.8	10.6	+25.7%
Net income attributable to owners of the parent	30.1	36.4	6.4	+21.1%

Naphtha price (¥/kL, domestic)	39,100	48,700	9,600
¥/US\$ exchange rate (market average)	111	109	(2)
¥/€ exchange rate (market average)	122	130	8

Statements of income

(¥ billion)

	Q1 2017		Q1 2018		Increase (decrease)	% change
		% of sales		% of sales		
Net sales	448.7	100.0%	489.8	100.0%	41.0	+9.1%
Cost of sales	302.1	67.3%	328.4	67.1%	26.3	+8.7%
Gross profit	146.6	32.7%	161.4	32.9%	14.8	+10.1%
Selling, general and administrative expenses	108.7	24.2%	113.5	23.2%	4.7	+4.3%
Operating income	37.9	8.4%	47.9	9.8%	10.0	+26.5%
Net non-operating income (expenses)	3.3		3.9		0.5	
of which,						
net financing income (expense)	1.3		2.0		0.7	
net equity in earnings (losses) of affiliates	2.6		2.5		(0.1)	
foreign exchange gains (loss)	(0.5)		(0.5)		0.1	
Ordinary income	41.2	9.2%	51.8	10.6%	10.6	+25.7%
Net extraordinary income (loss)	4.4		6.0		1.6	
Income before income taxes	45.6		57.7		12.2	
Income taxes	(15.0)		(20.8)		(5.8)	
Net income attributable to non-controlling interests	(0.5)		(0.6)		(0.0)	
Net income attributable to owners of the parent	30.1	6.7%	36.4	7.4%	6.4	+21.1%

Balance sheets

(¥ billion)

	At end of Mar. 2018	At end of Jun. 2018	Increase (decrease)		At end of Mar. 2018	At end of Jun. 2018	Increase (decrease)
Current assets	938.9	973.2	34.2	Liabilities	1,001.9	1,038.2	36.2
Cash and deposits	156.3	187.0	30.7	Current liabilities	589.1	620.7	31.6
Notes and accounts receivable—trade	341.4	326.4	(15.0)	Noncurrent liabilities ¹	412.8	417.4	4.6
Inventories	359.7	386.4	26.8	Net assets	1,305.2	1,322.1	16.9
Other current assets ¹	81.5	73.3	(8.2)	Shareholders' equity	1,160.8	1,169.4	8.6
Noncurrent assets	1,368.2	1,387.1	18.9	Capital stock	103.4	103.4	—
Property, plant and equipment	562.0	572.8	10.8	Capital surplus	79.4	79.4	0.0
Intangible assets	414.6	427.6	13.0	Retained earnings	981.9	990.5	8.6
Investments and other assets ¹	391.5	386.7	(4.9)	Treasury stock	(3.9)	(3.9)	(0.0)
				Accumulated other comprehensive income	126.6	135.0	8.5
				Non-controlling interests	17.8	17.7	(0.1)
Total assets ¹	2,307.2	2,360.3	53.2	Total liabilities and net assets ¹	2,307.2	2,360.3	53.2
Interest-bearing debt	301.7	346.0	44.3				
D/E ratio	0.23	0.27	0.03				

¹ “Partial Amendments to Accounting Standard for Tax Effect Accounting” is applied from FY 2018. Accordingly, all deferred tax assets are shown under investments and other assets, and all deferred tax liabilities are shown under noncurrent liabilities. The figures at end of March 2018 have been revised retroactively to reflect the amendments.

Cash flows

(¥ billion)

	Q1 2017	Q1 2018
a. Net cash provided by (used in) operating activities	37.0	35.3
b. Net cash used in investing activities	(24.9)	(11.3)
c. Free cash flows [a+b]	12.1	24.0
d. Net cash provided by (used in) financing activities	(9.9)	11.2
e. Effect of exchange rate change on cash and cash equivalents	5.6	1.0
f. Net increase (decrease) in cash and cash equivalents [c+d+e]	7.7	36.2
g. Cash and cash equivalents at beginning of period	144.1	148.6
h. Increase in cash and cash equivalents resulting from changes in scope of consolidation	0.3	1.0
i. Cash and cash equivalents at end of period [f+g+h]	152.1	185.8

Sales and operating income by segment¹

(¥ billion)

		Sales			Operating income		
		Q1 2017	Q1 2018	Increase (decrease)	Q1 2017	Q1 2018	Increase (decrease)
Material segment	Fibers	32.0	36.2	4.2	3.5	3.9	0.4
	Chemicals	178.3	205.6	27.3	22.5	28.6	6.0
	Electronics	36.5	38.4	1.9	2.0	2.5	0.5
	Material segment	246.8	280.2	33.4	28.0	34.9	6.9
Homes segment	Homes	115.6	115.7	0.1	6.9	7.1	0.1
	Construction Materials	12.6	13.0	0.3	0.7	0.8	0.1
	Homes segment	128.3	128.7	0.4	7.6	7.8	0.2
Health Care segment	Health Care	32.7	34.7	1.9	5.3	7.2	1.9
	Critical Care	37.3	41.7	4.3	3.7	5.1	1.4
	Health Care segment	70.1	76.3	6.2	9.0	12.3	3.3
Others		3.6	4.6	1.0	0.0	0.6	0.6
Corporate expenses and eliminations		—	—	—	(6.8)	(7.6)	(0.9)
Consolidated		448.7	489.8	41.0	37.9	47.9	10.0

¹ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.

Sales and operating income increase/decrease by business category¹ (i)

(¥ billion)

		Q1 2017	Q1 2018	Net Increase (decrease)	Increase(decrease) due to:				
					Sales volume	Sales prices	of which, due to foreign exchange	Others	Operating costs and others
Fibers	Sales	32.0	36.2	4.2	3.2	0.5	(0.1)	0.5	—
	Operating income	3.5	3.9	0.4	0.5			—	(0.6)
Chemicals	Sales	178.3	205.6	27.3	19.0	7.9	(0.6)	0.4	—
	Operating income	22.5	28.6	6.0	3.5			—	(5.4)
Electronics	Sales	36.5	38.4	1.9	3.8	(1.8)	(0.3)	(0.1)	—
	Operating income	2.0	2.5	0.5	0.6			—	1.7
Homes	Sales	115.6	115.7	0.1	(1.9)	0.4	—	1.6	—
	Operating income	6.9	7.1	0.1	(0.4)			—	0.1
Construction Materials	Sales	12.6	13.0	0.3	0.3	0.0	—	—	—
	Operating income	0.7	0.8	0.1	0.1			—	(0.1)

¹ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.


Sales and operating income increase/decrease by business category¹ (ii)

(¥ billion)

		Q1 2017	Q1 2018	Net increase (decrease)	Increase (decrease) due to:				
					Sales volume	Sales prices	of which, due to foreign exchange	Others	Operating costs and others
Health Care	Sales	32.7	34.7	1.9	1.8	(0.2)	(0.0)	0.3	—
	Operating income	5.3	7.2	1.9	1.5			—	0.6
Critical Care	Sales	37.3	41.7	4.3	3.1	2.0	0.4	(0.8)	—
	Operating income	3.7	5.1	1.4	1.7			—	(2.3)
Others	Sales	3.6	4.6	1.0	1.0	—	—	—	—
	Operating income	0.0	0.6	0.6	0.7			—	(0.1)
Corporate expenses and eliminations	Operating loss	(6.9)	(7.8)	(0.9)	—	—	—	—	(0.9)
Consolidated	Sales	448.7	489.8	41.0	30.2	8.8	(0.6)	2.0	—
	Operating income	37.9	47.9	10.0	8.4			—	(7.2)

¹ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.

Fibers



Review of operations

Impact of higher feedstock costs. Increased shipments of Lamous microfiber suede and Bemliese continuous-filament cellulose nonwoven. Sales and operating income increase.

Highlights


- July, decision to acquire Sage Automotive Interiors, Inc., a US-based manufacturer of automotive interior material.



¹ Increase (decrease) in sales prices excluding impact of foreign exchange.


² Impact of foreign exchange on sales prices.

Chemicals



Sales
increases/decreases due to:

Operating income
increases/decreases due to:



Review of operations

Petrochemicals:

Improved terms of trade for acrylonitrile.
Absence of impact of maintenance turnaround at naphtha cracker of Asahi Kasei Mitsubishi Chemical Ethylene Corp. Sales and operating income increase.

Performance polymers:

Firm sales of engineering plastics.
Deteriorated terms of trade for synthetic rubber. Sales and operating income decrease.

Performance materials & consumables:

Firm sales of ion-exchange membranes.
Decreased shipments of electronic materials.
Sales increase, and operating income flat.


Highlights

- July, receipt of Altair Enlighten Award 2018 for a Glass Fiber Reinforced Polyamide 66 Pedal Bracket.

¹ Increase (decrease) in sales prices excluding impact of foreign exchange.


² Impact of foreign exchange on sales prices.

Electronics



Sales
increases/decreases due to:

Operating income
increases/decreases due to:



¹ Increase (decrease) in sales prices excluding impact of foreign exchange.

² Impact of foreign exchange on sales prices.

Review of operations

Separators:

Increased shipments of Li-ion battery separator.
Sales and operating income increase.

Electronic devices:

Decreased sales of camera module devices for smartphones. Effect of consolidation of Senseair AB. Sales flat, and operating income decrease.

Highlights


- April, consolidation of Senseair AB, a Swedish manufacturer of gas sensor modules.

Homes

(¥ billion)

Sales

Operating income



Review of operations

Order-built homes:

- Decreased deliveries of Hebel Haus unit homes. Increased SG&A expenses such as labor costs and advertising expenses. Sales and operating income decrease.
- Year-on-year 7.0% increase in value of new orders, centered on unit homes.

Real estate, remodeling and others:


Firm performance of rental management and condominium construction in real estate. Sales and operating income increase.

Highlights

- May, launch of Hebel Haus product featuring semi-outdoor space connecting the living room and entrance approach.

	Q1 2017		Q1 2018		Increase (decrease)	
	Sales	Operating income	Sales	Operating income	Sales	Operating income
Order-built homes, etc. (Asahi Kasei Homes)	72.3	2.4	68.9	1.6	(3.4)	(0.8)
Real estate (Asahi Kasei Realty & Residence)	30.5	4.5	34.1	5.4	3.6	0.9
Remodeling (Asahi Kasei Reform)	12.5		12.3		(0.2)	
Other housing-related, etc.	0.4		0.5		0.1	
Total	115.6	6.9	115.7	7.1	0.1	0.1


Construction Materials




Review of operations

Impact of higher feedstock costs. Firm sales of each product. Sales and operating income flat.


Sales
increases/decreases due to:




Operating income
increases/decreases due to:




Health Care



Sales
increases/decreases due to:



Operating income
increases/decreases due to:



Review of operations

Pharmaceuticals:

Increased shipments of Teribone osteoporosis drug. Impact of reduced reimbursement prices and competition from generics. Sales decrease, and operating income flat.

Devices:

Increased shipments of Planova virus removal filters. Sales and operating income increase.


Highlights

- July, entry into distribution agreement with Stanbio Laboratory for the marketing of Lucica Glycated Albumin-L in the US.
- August, announcement of preliminary results of overseas Phase III clinical study for ART-123 (recombinant thrombomodulin alfa) for the treatment of severe sepsis with coagulopathy.

¹ Increase (decrease) in sales prices excluding impact of foreign exchange.

² Impact of foreign exchange on sales prices.

Critical Care



Review of operations

Increased shipments of defibrillators for professional use. Firm performance of LifeVest wearable defibrillator business. Sales and operating income increase.

Financial performance of Critical Care business category

(\$ million)

		FY 2017				FY 2018		Q1 2017 vs Q1 2018	% change	
		Q1	H1	H2		H1				
						Q1	forecast			
Net sales		336	686	762	1,448	382	776	46	13.7%	
	Gross operating income before PPA ¹ impact		64	138	162	300	77	155	13	
	Amortization/depreciation from PPA ¹ revaluation		(31)	(61)	(61)	(122)	(30)	(60)	1	
	Goodwill		(19)	(38)	(38)	(75)	(19)	(37)	0	
	Other intangible assets, etc.		(12)	(23)	(23)	(47)	(11)	(23)	1	
Consolidated operating income		33	77	102	179	47	95	13	40.2%	

¹ Purchase price allocation



2. Forecast for first half fiscal 2018

Consolidated operating performance forecast

(¥ billion)

	FY 2017			H1 2018 forecast			Increase (decrease) b-a	H1 2018 forecast in May c	Increase (decrease) b-c
	H1 a	H2	Total	Q1	Q2 forecast	Total b			
Net sales	964.7	1,077.5	2,042.2	489.8	555.2	1,045.0	80.3	1,037.0	8.0
Operating income	92.7	105.8	198.5	47.9	49.1	97.0	4.3	85.5	11.5
Ordinary income	98.2	114.4	212.5	51.8	51.7	103.5	5.3	90.5	13.0
Net income attributable to owners of the parent	70.9	99.4	170.2	36.4	42.1	78.5	7.6	62.5	16.0

Key operating factors

Naphtha price (¥/kL, domestic)	37,600	46,250	41,925	48,700	53,000	50,850	13,250	50,000	850
¥/US\$ exchange rate (market average)	111	111	111	109	110	110	(2)	105	5
¥/€ exchange rate (market average)	126	133	130	130	130	130	4	130	0

Dividends per share	¥14	¥20	¥34
---------------------	-----	-----	-----

¥17 (planned)

Sales and operating income forecast by segment

Sales forecast

(¥ billion)

	FY 2017			H1 2018 forecast			Increase (decrease) b-a	H1 2018 forecast in May c	Increase (decrease) b-c
	Q1	Q2	Total a	Q1	Q2 forecast	Total b			
Material	246.8	272.1	518.9	280.2	295.8	576.0	57.1	577.0	(1.0)
Homes	128.3	167.4	295.7	128.7	174.3	303.0	7.3	303.0	—
Health Care	70.1	72.4	142.5	76.3	78.7	155.0	12.5	148.0	7.0
Others	3.6	4.0	7.6	4.6	6.4	11.0	3.4	9.0	2.0
Consolidated	448.7	516.0	964.7	489.8	555.2	1,045.0	80.3	1,037.0	8.0

Operating income forecast

(¥ billion)

	FY 2017			H1 2018 forecast			Increase (decrease) b-a	H1 2018 forecast in May c	Increase (decrease) b-c
	Q1	Q2	Total b	Q1	Q2 forecast	Total b			
Material	28.0	32.7	60.7	34.9	31.6	66.5	5.8	59.0	7.5
Homes	7.6	18.6	26.1	7.8	17.2	25.0	(1.1)	24.0	1.0
Health Care	9.0	9.4	18.4	12.3	7.7	20.0	1.6	17.0	3.0
Others	0.0	0.6	0.7	0.6	0.4	1.0	0.3	1.0	—
Corporate expenses and eliminations	(6.8)	(6.5)	(13.3)	(7.6)	(7.9)	(15.5)	(2.2)	(15.5)	—
Consolidated	37.9	54.8	92.7	47.9	49.1	97.0	4.3	85.5	11.5

Sales forecast by business category

(¥ billion)

	H1 2017			H1 2018 forecast			Increase (decrease) b-a	H1 2018 forecast in May c	Increase (decrease) b-c
	Q1	Q2	Total a	Q1	Q2 forecast	Total b			
Fibers	32.0	34.1	66.1	36.2	36.8	73.0	6.9	73.0	—
Chemicals	178.3	196.8	375.2	205.6	219.4	425.0	49.8	425.0	—
Electronics	36.5	41.2	77.7	38.4	39.6	78.0	0.3	79.0	(1.0)
Homes	115.6	154.0	269.6	115.7	159.3	275.0	5.4	275.0	—
Construction Materials	12.6	13.5	26.1	13.0	15.0	28.0	1.9	28.0	—
Health Care	32.7	33.6	66.3	34.7	35.3	70.0	3.7	69.0	1.0
Critical Care	37.3	38.8	76.2	41.7	43.3	85.0	8.8	79.0	6.0
Others	3.6	4.0	7.6	4.6	6.4	11.0	3.4	9.0	2.0
Consolidated	448.7	516.0	964.7	489.8	555.2	1,045.0	80.3	1,037.0	8.0

Operating income forecast by business category¹

(¥ billion)

	H1 2017			H1 2018 forecast			Increase (decrease) b-a	H1 2018 forecast in May c	Increase (decrease) b-c
	Q1	Q2	Total a	Q1	Q2 forecast	Total b			
Fibers	3.5	3.1	6.6	3.9	3.1	7.0	0.4	6.5	0.5
Chemicals	22.5	26.0	48.6	28.6	26.9	55.5	6.9	49.0	6.5
Electronics	2.0	3.6	5.6	2.5	1.5	4.0	(1.6)	3.5	0.5
Homes	6.9	17.3	24.3	7.1	15.9	23.0	(1.3)	22.0	1.0
Construction Materials	0.7	1.1	1.8	0.8	1.2	2.0	0.2	2.0	–
Health Care	5.3	4.6	9.9	7.2	2.3	9.5	(0.4)	8.5	1.0
Critical Care	3.7	4.8	8.5	5.1	5.4	10.5	2.0	8.5	2.0
Others	0.0	0.6	0.7	0.6	0.4	1.0	0.3	1.0	–
Corporate expenses and eliminations	(6.9)	(6.4)	(13.3)	(7.8)	(7.7)	(15.5)	(2.2)	(15.5)	–
Consolidated	37.9	54.8	92.7	47.9	49.1	97.0	4.3	85.5	11.5

¹ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.



3. Appendix

Quarterly sales by business category

(¥ billion)

	FY 2017				FY 2018	FY 2018
	Q1	Q2	Q3	Q4	Q1	Q2 forecast
Fibers	32.0	34.1	34.7	35.1	36.2	36.8
Chemicals	178.3	196.8	214.1	210.1	205.6	219.4
Electronics	36.5	41.2	39.8	35.0	38.4	39.6
Homes	115.6	154.0	134.7	183.9	115.7	159.3
Construction Materials	12.6	13.5	14.5	12.1	13.0	15.0
Health Care	32.7	33.6	36.7	32.7	34.7	35.3
Critical Care	37.3	38.8	40.8	43.5	41.7	43.3
Others	3.6	4.0	4.4	5.2	4.6	6.4
Total	448.7	516.0	519.8	557.7	489.8	555.2

Quarterly operating income by business category¹

(¥ billion)

	FY 2017				FY 2018	FY 2018
	Q1	Q2	Q3	Q4	Q1	Q2 forecast
Fibers	3.5	3.1	3.0	2.6	3.9	3.1
Chemicals	22.5	26.0	30.1	21.4	28.6	26.9
Electronics	2.0	3.6	3.7	0.4	2.5	1.5
Homes	6.9	17.3	11.9	24.0	7.1	15.9
Construction Materials	0.7	1.1	1.7	0.5	0.8	1.2
Health Care	5.3	4.6	8.2	1.6	7.2	2.3
Critical Care	3.7	4.8	5.4	5.9	5.1	5.4
Others	0.0	0.6	0.4	0.8	0.6	0.4
Corporate expenses and eliminations	(6.9)	(6.4)	(7.9)	(7.9)	(7.8)	(7.7)
Total	37.9	54.8	56.5	49.3	47.9	49.1

¹ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.

Overseas sales by business category

(¥ billion)

	Q1 2017			Q1 2018			Increase (decrease)	% change
	Total sales	Overseas sales	% of total	Total sales	Overseas sales	% of total		
Fibers	32.0	14.2	44.4%	36.2	17.5	48.4%	3.3	+23.1%
Chemicals	178.3	88.8	49.8%	205.6	104.6	50.9%	15.9	+17.9%
Electronics	36.5	24.5	67.1%	38.4	27.0	70.4%	2.6	+10.5%
Homes	115.6	—	—	115.7	—	—	—	—
Construction Materials	12.6	—	—	13.0	0.0	0.1%	0.0	—
Health Care	32.7	9.2	28.0%	34.7	11.6	33.5%	2.4	+26.5%
Critical Care	37.3	36.9	98.9%	41.7	41.2	99.0%	4.3	+11.7%
Others	3.6	0.7	20.0%	4.6	0.6	12.5%	(0.1)	-20.0%
Total	448.7	174.3	38.8%	489.8	202.6	41.4%	28.3	+16.3%
Asia		97.2	21.7%		119.3	24.4%	22.1	+22.7%
of which, sales to China		41.4	9.2%		52.5	10.7%	11.2	+27.0%
US		49.6	11.1%		55.0	11.2%	5.4	+10.9%
Europe		23.2	5.2%		23.5	4.8%	0.3	+1.4%
Other countries		4.3	1.0%		4.8	1.0%	0.5	+12.4%

Sales, excluding Homes
and Construction Materials

320.5 174.3 54.4% 361.1 202.6 56.1%

Extraordinary income and loss

(¥ billion)

		Q1 2017	Q1 2018	Increase (decrease)
	Gain on sales of investment securities	5.5	6.8	1.3
	Gain on sales of noncurrent assets	0.4	0.1	(0.3)
	Total extraordinary income	5.9	6.9	1.0
	Loss on valuation of investment securities	0.0	—	(0.0)
	Loss on disposal of noncurrent assets	0.7	0.5	(0.2)
	Impairment losses	0.5	0.2	(0.3)
	Business structure improvement expenses	0.4	0.3	(0.1)
	Total extraordinary loss	1.6	0.9	(0.7)
	Net extraordinary income (loss)	4.4	6.0	1.6

Homes

(¥ billion, % indicates year-on-year comparison)

		Value of new orders during the term	Sales of order-built homes, etc. ¹	Sales of real estate ¹				Sales of remodeling	Other sales	Consolidated	Order backlog
				Pre-built homes	Rental housing	Other	Total				
FY14	H1	217.6 (-13.6%)	187.9 (+3.9%)	9.8	29.3	1.4	40.6	26.3	1.1	256.0 (+7.4%)	516.3
	H2	208.0 (+22.8%)	216.2 (+1.5%)	18.0	31.8	1.6	51.4	27.3	0.9	295.8 (-0.1%)	514.5
	annual	425.7 (+1.0%)	404.2 (+2.6%)	27.8	61.1	3.1	92.0	53.6	2.0	551.8 (+3.3%)	
FY15	H1	217.3 (-0.2%)	183.8 (-2.2%)	10.4	33.5	1.7	45.6	27.8	0.9	258.0 (+0.8%)	554.6
	H2	183.1 (-12.0%)	227.7 (+5.3%)	27.7	39.0	1.8	68.4	28.1	0.7	325.0 (+9.9%)	513.1
	annual	400.4 (-5.9%)	411.5 (+1.8%)	38.1	72.5	3.5	114.1	55.9	1.6	583.0 (+5.7%)	
FY16	H1	206.6 (-4.9%)	183.5 (-0.1%)	11.8	41.2	1.8	54.8	27.0	(0.5)	264.8 (+2.6%)	538.8
	H2	194.3 (+6.1%)	220.8 (-3.1%)	9.5	43.5	1.6	54.6	29.1	0.8	305.3 (-6.1%)	515.8
	annual	400.9 (+0.1%)	404.3 (-1.8%)	21.3	84.7	3.4	109.4	56.1	0.4	570.2 (-2.2%)	
FY17	Q1	91.6 (-5.0%)	72.3 (-4.6%)	7.3	22.4	0.7	30.5	12.5	0.4	115.6 (-0.1%)	536.3
	Q2	101.4 (-7.9%)	110.4 (+2.5%)	4.8	22.9	0.9	28.5	14.3	0.7	154.0 (+3.2%)	528.9
	H1	193.1 (-6.5%)	182.7 (-0.4%)	12.0	45.3	1.6	59.0	26.8	1.1	269.6 (+1.8%)	
	H2	212.5 (+9.4%)	224.1 (+1.5%)	14.7	47.8	2.5	65.1	28.4	1.1	318.7 (+4.4%)	520.9
	annual	405.6 (+1.2%)	406.8 (+0.6%)	26.8	93.2	4.2	124.1	55.2	2.2	588.3 (+3.2%)	
FY18	Q1	98.1 (+7.0%)	68.9 (-4.7%)	8.7	24.6	0.8	34.1	12.3	0.5	115.7 (+0.1%)	551.1
	Q2 forecast	110.5 (+9.0%)	108.4 (-1.8%)	7.8	25.1	1.3	34.3	15.8	0.8	159.3 (+3.4%)	554.9
	H1 forecast	208.6 (+8.0%)	177.3 (-3.0%)	16.5	49.7	2.1	68.3	28.1	1.3	275.0 (+2.0%)	

¹ As the rental management operation of Asahi Kasei Homes was transferred to Asahi Kasei Realty & Residence, the corresponding sales previously included in order-built homes, etc., are combined with rental housing under real estate beginning with H2 2015.

Health Care (i)

Sales of Health Care business category

		FY 2017		FY 2018
		Q1	H1	Q1
	Domestic pharmaceuticals	15.6	30.5	14.7
	Others	1.2	2.8	1.5
	Asahi Kasei Pharma consolidated	16.8	33.3	16.2
	Devices ¹	15.9	33.0	18.5
	Total	32.7	66.3	34.7

¹Asahi Kasei Medical and its affiliate companies.

Main pharmaceuticals domestic sales

	FY 2017		FY 2018
	Q1	H1	Q1
Teribone	6.6	13.3	7.2
Recomodulin	2.8	5.8	2.9
Flivas	1.3	2.5	0.9
Bredinin	1.0	1.9	0.8
Elcitonin	1.0	1.9	0.7
Reclast	0.2	0.5	0.4

Health Care (ii)

Pharmaceutical pipeline

Development stage	Code name, form, generic name	Classifications	Indication	Region	Origin	Remarks
Phase III	ART-123, injection, recombinant thrombomodulin alfa	Anticoagulant	Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF)	Japan	In-house	Additional indication
	MN-10-T, autoinjection, teriparatide acetate	Osteoporosis drug	Osteoporosis with high risk of fracture	Japan	In-house	New formulation; new dose
	AK1820, injection/capsule, isavuconazole	Antifungal agent	Invasive fungal infections	Japan	Licensed	
Phase II	ART-123, injection, recombinant thrombomodulin alfa	Anticoagulant	Chemotherapy-induced peripheral neuropathy (CIPN)	Japan	In-house	Additional indication
Pending approval (overseas)	Flivas, tablet, naftopidil	Dysuria treatment	Benign prostatic hyperplasia	China	In-house	
Phase III (overseas)	ART-123, injection, recombinant thrombomodulin alfa	Anticoagulant	Severe sepsis with coagulopathy	United States, Europe, etc.	In-house	
	HE-69, tablet, mizoribine	Immunosuppressant	Lupus nephritis, nephrotic syndrome	China	In-house	Additional indication

(blank space for your notes)

Creating for Tomorrow

The commitment of the Asahi Kasei Group:

To do all that we can in every era to help the people of the world make the most of life and attain fulfillment in living.

Since our founding, we have always been deeply committed to contributing to the development of society, boldly anticipating the emergence of new needs.

This is what we mean by “Creating for Tomorrow.”

AsahiKASEI